Relmada Therapeutics lost more than two-thirds of its market value early Wednesday after the biotechnology company said a treatment for major depressive disorder would likely fail to meet its primary ...
Relmada Therapeutics' depression treatment is "unlikely" to meet the main goal of a late-stage trial, it said on Wednesday, citing an independent data monitoring committee's analysis. The treatment, ...